C WorldWide Group’s Aimmune Therapeutics AIMT Stock Holding History

C WorldWide Group’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-182,709	Closed	-$4.08M	–	117
2019 Q1	$4.08M	Buy	182,709 +48,377	+36%	+$1.14M	0.05%	67
2018 Q4	$3.21M	Sell	134,332 -73,850	-35%	-$1.91M	0.05%	61
2018 Q3	$5.68M	Sell	208,182 -38,567	-16%	-$1.09M	0.07%	60
2018 Q2	$6.63M	Buy	246,749 +123,466	+100%	+$3.78M	0.09%	56
2018 Q1	$3.92M	Sell	123,283 -417	-0.3%	-$14.7K	0.06%	61
2017 Q4	$4.68M	Sell	123,700 -107,200	-46%	-$3.46M	0.07%	61
2017 Q3	$5.72M	Sell	230,900 -17,900	-7%	-$386K	0.08%	60
2017 Q2	$5.12M	Buy	248,800 +60,700	+32%	+$1.16M	0.08%	61
2017 Q1	$4.09M	Buy	+188,100	New	+$3.86M	0.07%	61

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

C WorldWide Group's AIMT Position: Q2 2019 in Review

C WorldWide Group sold out of Aimmune Therapeutics (AIMT) in Q2 2019, closing a stake of 182,709 shares — an estimated $4.08M sold.

C WorldWide Group first reported a position in AIMT in Q1 2017 and held it in 9 quarters. The position peaked at $6.63M in Q2 2018. 125 funds tracked by Wall St. Rank hold AIMT as of Q2 2019.

C WorldWide Group reported no remaining Aimmune Therapeutics position as of Q2 2019 after selling out during the quarter.
C WorldWide Group sold 182,709 Aimmune Therapeutics shares in Q2 2019, an estimated $4.08M.
C WorldWide Group first reported a position in Aimmune Therapeutics in Q1 2017 and held it in 9 quarters.
C WorldWide Group's Aimmune Therapeutics position peaked at $6.63M in Q2 2018.
125 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2019.

Based on C WorldWide Group's 13F filing for Q2 2019, filed 2 Aug 2019.